Latest Interventional cardiology Stories

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

2013-05-17 04:20:42

NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint results for several trials will be presented, including the NG PROMUS trial, which evaluated our Promus PREMIER((TM))...

InspireMD to Announce Six-Month Results from the MGuard(TM) Embolic Protection Stent (EPS) MASTER Trial at EuroPCR

2013-05-16 20:22:40

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- -Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard(TM) Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a...

HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast

2013-05-16 16:25:36

FRAMINGHAM, Mass. and SYDNEY, May 16, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013. The conference is being held May 20-22, 2013 at the Sheraton New...

InspireMD Announces Reimbursement Coverage for MGuard(TM) Coronary Embolic Protection Stent (EPS) From Brazil's Largest Private Insurer

2013-05-16 12:30:16

- More than 18 Million Brazilians have Reimbursable Access to MGuard EPS - BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard(TM) Coronary Embolic Protection Stent (EPS) from UNIMED, Brazil's largest private health care insurer. Alan Milinazzo, InspireMD's President and CEO said,...

Biosensors to Acquire Assets of Spectrum Dynamics

2013-05-16 08:27:27

Interventional Cardiology Pioneer Aims to Offer Improved Detection of Cardiovascular Disease SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment...

Thoratec Presentation At Bank of America Merrill Lynch 2013 Health Care Conference To Be Webcast

2013-05-14 08:34:37

PLEASANTON, Calif., May 14, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Bank of America Merrill Lynch 2013 Health Care Conference on Thursday, May 16. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 10:40 a.m., Pacific Daylight Time (1:40 p.m.,...

HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast

2013-05-10 16:23:53

FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013. The conference is being held...

OrbusNeich enforces injunction against Boston Scientific in Germany

2013-05-07 12:31:03

WIESBADEN, Germany, May 7, 2013 /PRNewswire/ -- OrbusNeich Medical, Inc. and its German subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") announced that it has fulfilled all the requirements established by the Dusseldorf Regional Court, including posting of a performance bond and service to Counsel for the Defendants, and is today enforcing the Preliminary Injunction issued by the Court on April 30, 2013, against Boston Scientific Corporation and its German subsidiary...

Economic Growth In Latin America Fueling Strong Revenue Growth For Interventional Cardiology Devices

2013-05-02 08:37:52

Expanding Reimbursement Coverage to Drive Adoption of High-End Devices in the Long Term, According to Millennium Research Group TORONTO, May 2, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, favorable demographics and growing economies are the main factors spurring rising revenues in the Latin American interventional cardiology (IC) device market. Economic growth is contributing to increased...

Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs

2013-05-02 08:36:30

TEL AVIV, Israel, May 2, 2013 /PRNewswire/ -- Leviticus Cardio [http://www.leviticus-cardio.com ], a portfolio company of the Mofet Venture Accelerator [http://www.mofet-venture.com ], owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75% full system efficiency rate as compared with...